Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthonius de Boer

Showing results (111-120 of 308) with videos related to

Pageof 31
Sort By:
Arthritis & Rheumatology (Hoboken, N.J.)|February 8, 2014
Changes in mortality patterns following total hip or knee arthroplasty over the past two decades: a nationwide cohort studyArief Lalmohamed, Peter Vestergaard, Anthonius de Boer, et al.
British Journal of Clinical Pharmacology|July 27, 2022
Primary nonadherence to drugs prescribed by general practitioners: A Dutch database studyMirjam Hempenius, Simone Rijken, Rolf H H Groenwold, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|September 20, 2024
The minimal important difference in obsessive-compulsive disorder: An analysis of double-blind SSRI trials in adultsSem E Cohen, Jasper B Zantvoord, Taina K Mattila, et al.
Pharmacoepidemiology and Drug Safety|June 16, 2020
Rivaroxaban was found to be noninferior to warfarin in routine clinical care: A retrospective noninferiority cohort replication studyTurki A Althunian, Anthonius de Boer, Rolf H H Groenwold, et al.
British Journal of Clinical Pharmacology|June 21, 2005
Suboptimal choices and dosing of statins at start of therapyAukje K Mantel-Teeuwisse, Olaf H Klungel, Tom Schalekamp, et al.
Pharmacoepidemiology and Drug Safety|October 26, 2007
Comparing treatment effects after adjustment with multivariable Cox proportional hazards regression and propensity score methodsEdwin P Martens, Anthonius de Boer, Wiebe R Pestman, et al.
Clinical Pharmacology and Therapeutics|June 13, 2006
CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring?Tom Schalekamp, Gerard J J Boink, Loes E Visser, et al.
European Journal of Heart Failure|October 16, 2010
Non-selective vs. selective beta-blocker treatment and the risk of thrombo-embolic events in patients with heart failureOlav R de Peuter, Patrick C Souverein, Olaf H Klungel, et al.
Pharmacoepidemiology and Drug Safety|May 28, 2015
Are ECG monitoring recommendations before prescription of QT-prolonging drugs applied in daily practice? The example of haloperidolMiriam Jacoba Warnier, Frans Hendrik Rutten, Patrick Cyriel Souverein, et al.
Journal of the Renin-Angiotensin-Aldosterone System : JRAAS|June 9, 2009
Renin-angiotensin system polymorphisms and the association between use of angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors and the risk of diabetesOzlem Bozkurt, Anthonius de Boer, Diederik E Grobbee, et al.
Pageof 31

Showing results (111-120 of 308) with videos related to

Sort By:
Pageof 31
Arthritis & Rheumatology (Hoboken, N.J.)|February 8, 2014
Changes in mortality patterns following total hip or knee arthroplasty over the past two decades: a nationwide cohort studyArief Lalmohamed, Peter Vestergaard, Anthonius de Boer, et al.
British Journal of Clinical Pharmacology|July 27, 2022
Primary nonadherence to drugs prescribed by general practitioners: A Dutch database studyMirjam Hempenius, Simone Rijken, Rolf H H Groenwold, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|September 20, 2024
The minimal important difference in obsessive-compulsive disorder: An analysis of double-blind SSRI trials in adultsSem E Cohen, Jasper B Zantvoord, Taina K Mattila, et al.
Pharmacoepidemiology and Drug Safety|June 16, 2020
Rivaroxaban was found to be noninferior to warfarin in routine clinical care: A retrospective noninferiority cohort replication studyTurki A Althunian, Anthonius de Boer, Rolf H H Groenwold, et al.
British Journal of Clinical Pharmacology|June 21, 2005
Suboptimal choices and dosing of statins at start of therapyAukje K Mantel-Teeuwisse, Olaf H Klungel, Tom Schalekamp, et al.
Pharmacoepidemiology and Drug Safety|October 26, 2007
Comparing treatment effects after adjustment with multivariable Cox proportional hazards regression and propensity score methodsEdwin P Martens, Anthonius de Boer, Wiebe R Pestman, et al.
Clinical Pharmacology and Therapeutics|June 13, 2006
CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring?Tom Schalekamp, Gerard J J Boink, Loes E Visser, et al.
European Journal of Heart Failure|October 16, 2010
Non-selective vs. selective beta-blocker treatment and the risk of thrombo-embolic events in patients with heart failureOlav R de Peuter, Patrick C Souverein, Olaf H Klungel, et al.
Pharmacoepidemiology and Drug Safety|May 28, 2015
Are ECG monitoring recommendations before prescription of QT-prolonging drugs applied in daily practice? The example of haloperidolMiriam Jacoba Warnier, Frans Hendrik Rutten, Patrick Cyriel Souverein, et al.
Journal of the Renin-Angiotensin-Aldosterone System : JRAAS|June 9, 2009
Renin-angiotensin system polymorphisms and the association between use of angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors and the risk of diabetesOzlem Bozkurt, Anthonius de Boer, Diederik E Grobbee, et al.
Pageof 31